Journal article
Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat
Cancer biotherapy & radiopharmaceuticals, Vol.36(8), pp.632-641
10/01/2021
DOI: 10.1089/cbr.2020.4633
PMCID: PMC8817731
PMID: 34252288
Abstract
Background: Histone deacetylase (HDAC) inhibitors have been shown in preclinical studies to upregulate norepinephrine transporters in neuroblastoma and pheochromocytoma, and somatostatin receptors in pulmonary carcinoid, small cell lung cancer, and pancreatic neuroendocrine malignancies. This pilot imaging study in humans focuses on midgut neuroendocrine carcinoma metastatic to the liver, evaluating the effect of pretreatment with the HDAC inhibitor vorinostat on uptake of 123I-MIBG and 68Ga-DOTATOC.
Materials and Methods: Multiple midgut neuroendocrine liver metastases in clinically stable subjects were imaged with 123I-MIBG and 68Ga-DOTATOC before and after a 4-d course of vorinostat. Scans were performed with strict attention to detail and timed about 1 month apart occurring just before monthly long-acting octreotide administrations. Uptake changes in tumor and normal liver parenchyma were assessed on positron emission computed tomography (PET/CT) with standardized uptake values and on single photon emission computed tomography (SPECT) with qualitative ratio images.
Results: The experimental units were metastatic liver lesions within patients (n = 50). There was no significant difference in administered activity or uptake time between pairs of scans for either radiotracer. Statistically significant increase in maximum standardized uptake values (SUVmax) averaged over all lesions was noted on the 68Ga-DOTATOC PET scans (+11%, p < 0.01). SUVmax in normal liver showed no significant change (p = 0.12). There was no qualitative change in uptake of 123I-MIBG after vorinostat.
Conclusions: In this pilot imaging study in patients with midgut neuroendocrine liver metastases, a short course of the HDAC inhibitor vorinostat induced a statistically significant increase in SUVmax on 68Ga-DOTATOC PET/computed tomography (CT) imaging in some hepatic neuroendocrine tumor metastases. There was no significant effect of vorinostat on tumor uptake of 123I-MIBG on SPECT/CT imaging. Given the pilot nature of this trial, the findings merit further investigation with a more rigorous protocol evaluating longer pretreatment and different dosages of vorinostat or other HDAC inhibitors, as well as effects on the therapeutic capability of 177Lu- or 90Y-somatostatin analogs.
Details
- Title: Subtitle
- Potential for Increasing Uptake of Radiolabeled 68Ga-DOTATOC and 123I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat
- Creators
- Janet H Pollard - Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA., Iowa City Veterans Administration Health Care System, Iowa City, Iowa, USAYusuf Menda - Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USAK.D Zamba - Department of Biostatistics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USAMark Madsen - Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USAM. Sue O'Dorisio - Department of Pediatrics, and University of Iowa Carver College of Medicine, Iowa City, Iowa, USAThomas O'Dorisio - Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USADavid Bushnell - Department of Radiology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA., Iowa City Veterans Administration Health Care System, Iowa City, Iowa, USA
- Resource Type
- Journal article
- Publication Details
- Cancer biotherapy & radiopharmaceuticals, Vol.36(8), pp.632-641
- DOI
- 10.1089/cbr.2020.4633
- PMID
- 34252288
- PMCID
- PMC8817731
- ISSN
- 1084-9785
- eISSN
- 1557-8852
- Language
- English
- Date published
- 10/01/2021
- Academic Unit
- Radiology; Stead Family Department of Pediatrics; Biostatistics; Radiation Oncology; Endocrinology and Metabolism; Internal Medicine
- Record Identifier
- 9984214823002771
Metrics
33 Record Views